Israeli drug maker Teva Pharmaceutical Industries Ltd. said on Wednesday the Food and Drug Administration has granted final approval for the company’s generic treatment for patients with prostate cancer, and it will begin shipping the product immediately. The drug, called Mitoxantrone Hydrochloride injection USP, is used in combination with corticosteroids as initial treatment for patients [...]
Read The Full Article:
http://www.drilltools.org/289
Add to del.icio.us
Digg this
Post to Furl
Add to reddit
Add to myYahoo!
Powered by blogdig.net